bioRxiv · 10.1101/2023.02.25.530000
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
Abstract
Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (Mpro) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms ("fingerprints") and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Moghadasi, S. A., Biswas, R., Harki, D. A., Harris, R.. 2023-02-27. Rapid resistance profiling of SARS-CoV-2 protease inhibitors. https://doi.org/10.1101/2023.02.25.530000
Cite the original work for its findings. Save a collection to share your selection of sources.